Jaeyong Ahn & Altor BioScience

Jaeyong Ahn: Jaeyong Ahn>>>, CEO of Altor BioScience>>>, expressed commitment to global public health through the development of the rotavirus vaccine.

Altor BioScience: Altor BioScience has licensed vaccine technology from the United States — Centers for Disease Control and Prevention>>> and is developing an injectable rotavirus vaccine, which could significantly expand its market presence and contribute to global health.

Jaeyong Ahn: Jaeyong Ahn, CEO of Altor BioScience, expressed the company's commitment to investing in pipeline development and manufacturing infrastructure following the Canada — Canada Growth Fund selection.

Altor BioScience: Altor BioScience secured KRW 300 billion in financing from the Canada — Canada Growth Fund, which will accelerate the development of its pneumococcal vaccine candidate GBP410 and enhance its manufacturing capabilities. This funding strengthens its position in the global vaccine market and contributes to Korea's vaccine sovereignty.